125 related articles for article (PubMed ID: 36821465)
21. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
22. Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study.
Li Z; Zhu H; Pang X; Mao Y; Yi X; Li C; Lei M; Cheng X; Liang L; Wu J; Ding Y; Yang J; Sun Y; Zhang T; You D; Liu Z
BMC Cancer; 2022 Sep; 22(1):962. PubMed ID: 36076189
[TBL] [Abstract][Full Text] [Related]
23. Central, But Not Peripheral, Circulating Tumor Cells are Prognostic in Patients Undergoing Resection of Colorectal Cancer Liver Metastases.
Connor AA; McNamara K; Al-Sukhni E; Diskin J; Chan D; Ash C; Lowes LE; Allan AL; Zogopoulos G; Moulton CA; Gallinger S
Ann Surg Oncol; 2016 Jul; 23(7):2168-75. PubMed ID: 26714949
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of circulating tumor cells and hematological parameters in 617 Chinese patients with colorectal cancer: retrospective analysis.
He Y; He X; Zhou Y; Luo S
BMC Cancer; 2023 Jul; 23(1):707. PubMed ID: 37507669
[TBL] [Abstract][Full Text] [Related]
25. Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and CEA as the Potential Prognostic Biomarkers for Colorectal Cancer.
Ming-Sheng F; Mei-Ling D; Xun-Quan C; Yuan-Xin H; Wei-Jie Z; Qin-Cong P
Can J Gastroenterol Hepatol; 2022; 2022():3109165. PubMed ID: 35028301
[TBL] [Abstract][Full Text] [Related]
26. MiSelect R System: the validation of a new detection system of CTCs and their correlation with prognosis in non-metastatic CRC patients.
Lin CC; Yang CY; Hung TC; Wang CH; Wei SW; Schiro P; Tseng JY; Lin CH; Jiang JK
Sci Rep; 2023 Mar; 13(1):4773. PubMed ID: 36959311
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy.
Zhang D; Zhao L; Zhou P; Ma H; Huang F; Jin M; Dai X; Zheng X; Huang S; Zhang T
Cancer Cell Int; 2017; 17():6. PubMed ID: 28070168
[TBL] [Abstract][Full Text] [Related]
28. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
Yang XQ; Chen C; Wang FB; Peng CW; Li Y
Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer.
Cai D; Huang ZH; Yu HC; Wang XL; Bai LL; Tang GN; Peng SY; Li YJ; Huang MJ; Cao GW; Wang JP; Luo YX
World J Gastroenterol; 2019 Sep; 25(33):4945-4958. PubMed ID: 31543685
[TBL] [Abstract][Full Text] [Related]
30. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
Chen Y; Zou TN; Wu ZP; Zhou YC; Gu YL; Liu X; Jin CG; Wang XC
Int J Biol Markers; 2010; 25(2):59-68. PubMed ID: 20586026
[TBL] [Abstract][Full Text] [Related]
31. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer.
Hermunen K; Soveri LM; Boisen MK; Mustonen HK; Dehlendorff C; Haglund CH; Johansen JS; Osterlund P
Acta Oncol; 2020 Dec; 59(12):1416-1423. PubMed ID: 32790589
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial.
Riethdorf S; Müller V; Loibl S; Nekljudova V; Weber K; Huober J; Fehm T; Schrader I; Hilfrich J; Holms F; Tesch H; Schem C; von Minckwitz G; Untch M; Pantel K
Clin Cancer Res; 2017 Sep; 23(18):5384-5393. PubMed ID: 28679772
[No Abstract] [Full Text] [Related]
33. Combined preoperative CEA and CD44v6 improves prognostic value in patients with stage I and stage II colorectal cancer.
Chen L; Jiang B; Wang Z; Liu M; Yang H; Xing J; Zhang C; Yao Z; Zhang N; Cui M; Su X
Clin Transl Oncol; 2014 Mar; 16(3):285-92. PubMed ID: 23860725
[TBL] [Abstract][Full Text] [Related]
34. CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242.
Björkman K; Mustonen H; Kaprio T; Kekki H; Pettersson K; Haglund C; Böckelman C
Tumour Biol; 2021; 43(1):57-70. PubMed ID: 33935125
[TBL] [Abstract][Full Text] [Related]
35. Early Postoperative Serum Carcinoembryonic Antigen Is a Stronger Independent Prognostic Factor for Stage II Colorectal Cancer Patients Than T4 Stage and Preoperative CEA.
Fenqi D; Yupeng L; Qiuju Z; Chao Y; Wenjie S; Tianyi X; Junnan G; Weinan X; Xiufeng J; Junge B; Chenyang J; Hua X; Yien L; Xuefeng B; Yanlong L
Front Oncol; 2021; 11():758509. PubMed ID: 35087748
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of epithelial-mesenchymal transition typing of circulating tumour cells in colorectal cancer.
Hou J; Guo C; Lyu G
Colorectal Dis; 2020 May; 22(5):581-587. PubMed ID: 31868956
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer.
Abdalla TSA; Meiners J; Riethdorf S; König A; Melling N; Gorges T; Karstens KF; Izbicki JR; Pantel K; Reeh M
PLoS One; 2021; 16(6):e0252897. PubMed ID: 34111181
[TBL] [Abstract][Full Text] [Related]
38. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer.
Pesta M; Fichtl J; Kulda V; Topolcan O; Treska V
Anticancer Res; 2013 May; 33(5):2239-43. PubMed ID: 23645782
[TBL] [Abstract][Full Text] [Related]
40. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
